Literature DB >> 21411741

Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction.

Thenappan Thenappan1, Sanjiv J Shah, Mardi Gomberg-Maitland, Brett Collander, Ajay Vallakati, Pranavkumar Shroff, Stuart Rich.   

Abstract

BACKGROUND: Pulmonary vascular disease associated with left-side heart failure and preserved ejection fraction (PH-HFpEF) is an increasingly common cause of pulmonary hypertension. The distinction between PH-HFpEF and pulmonary arterial hypertension (PAH) is important because therapies indicated for PAH can be detrimental in HFpEF. The characteristic features of PH-HFpEF are understudied. METHODS AND
RESULTS: In a cross-sectional study, we compared the clinical, echocardiographic, and hemodynamic features of PH-HFpEF (n=100), with PAH (n=522), and HFpEF without pulmonary vascular disease (n=45). We determined the clinical characteristics that best differentiated PH-HFpEF from PAH. Compared with patients with PAH, patients with PH-HFpEF were older; had a higher prevalence of cardiovascular comorbidities; had worse exercise capacity and renal function; more frequently had left atrial enlargement; and less frequently had right atrial enlargement. PH was less severe in PH-HFpEF patients than in PAH patients (pulmonary vascular resistance 4.8 [interquartile range 3 to 8.4] versus 10.9 [interquartile range 7.4 to 15.7] Wood units; P<0.001). Old age, the presence of hypertension and coronary artery disease, the absence of right atrial enlargement, higher aortic systolic pressure, higher mean right atrial pressure, and higher cardiac output best differentiated PH-HFpEF from PAH (area under the receiver operating characteristics curve; curve 0.97). Compared with HFpEF patients without pulmonary hypertension, PH-HFpEF patients were often female and more symptomatic, more often had right ventricular hypertrophy and right atrial enlargement, and had higher right atrial pressure.
CONCLUSIONS: These data should help better identify PH-HFpEF, an entity that has become increasingly recognized and difficult to treat.

Entities:  

Mesh:

Year:  2011        PMID: 21411741     DOI: 10.1161/CIRCHEARTFAILURE.110.958801

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  80 in total

Review 1.  Metabolic Syndrome and the Lung.

Authors:  Cynthia W Baffi; Lisa Wood; Daniel Winnica; Patrick J Strollo; Mark T Gladwin; Loretta G Que; Fernando Holguin
Journal:  Chest       Date:  2016-01-20       Impact factor: 9.410

Review 2.  Towards Precision in HF Pharmacotherapy.

Authors:  Nicholas B Norgard; Carolyn Hempel
Journal:  Curr Heart Fail Rep       Date:  2017-02

3.  Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection Fraction.

Authors:  Nadine Al-Naamani; Ioana R Preston; Jessica K Paulus; Nicholas S Hill; Kari E Roberts
Journal:  JACC Heart Fail       Date:  2015-06       Impact factor: 12.035

Review 4.  Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.

Authors:  Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

5.  Contribution of the left atrial remodeling to the elevated pulmonary capillary wedge pressure in patients with WHO Group II pulmonary hypertension.

Authors:  Scott L Purga; Maria G Karas; Evelyn M Horn; Mikhail T Torosoff
Journal:  J Echocardiogr       Date:  2018-11-24

6.  Case series of 5 patients with end-stage renal disease with reversible dyspnea, heart failure, and pulmonary hypertension related to arteriovenous dialysis access.

Authors:  Farhan Raza; Mohamad Alkhouli; Frances Rogers; Anjali Vaidya; Paul Forfia
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

7.  Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rebecca R Vanderpool; Melissa Saul; Mehdi Nouraie; Mark T Gladwin; Marc A Simon
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

Review 8.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

Review 9.  World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.

Authors:  Kurt W Prins; Thenappan Thenappan
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

10.  High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension.

Authors:  Ivan M Robbins; Anna R Hemnes; Meredith E Pugh; Evan L Brittain; David X Zhao; Robert N Piana; Pete P Fong; John H Newman
Journal:  Circ Heart Fail       Date:  2013-12-02       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.